Foxo4-DRI vs Humanin

D-retro-inverso peptide that disrupts Foxo4/p53 interaction in senescent cells; restores p53-mediated apoptosis selectively in senescent cells; clears cellular "zombie cells"

FOXO4-DRI is a synthetic D-amino acid retro-inverso (DRI) peptide that disrupts the interaction between the FOXO4 transcription factor and p53 in senescent cells, triggering apoptosis selectively in cells with an activated senescent secretory phenotype (SASP) while sparing non-senescent cells in which this interaction is not tonically antiapoptotic. In senescent cells, overexpressed FOXO4 sequesters p53 in the nucleus and prevents it from initiating apoptosis, enabling the persistence of metabolically active senescent cells that secrete pro-inflammatory SASP cytokines; FOXO4-DRI competitively disrupts this FOXO4-p53 interaction, freeing p53 to activate its apoptotic transcriptional program specifically in cells where the FOXO4 sequestration is functionally relevant. The foundational study published in Cell demonstrated that FOXO4-DRI selectively induced apoptosis in senescent cells in vivo in mice, restoring tissue homeostasis in both chemotherapy-induced and naturally aged animals; subsequent molecular modeling work has characterized the FOXO4-TP53 interaction interface to guide further senolytic peptide design, though published evidence in humans is absent and the preclinical literature remains limited. FOXO4-DRI is a research compound with no regulatory approval in any jurisdiction; it has been studied only in preclinical animal models, and no human pharmacokinetic, safety, or clinical efficacy data has been established.

Mitochondria-derived peptide; binds gp130 receptor, activates STAT3/JAK pathway; inhibits BAX-mediated apoptosis; improves insulin sensitivity

Humanin is a mitochondrially encoded 21-amino-acid peptide originally identified through its capacity to suppress neuronal apoptosis induced by familial Alzheimer's disease gene products, now recognized as a founding member of the class of mitochondrial-derived peptides (MDPs) with broad cytoprotective actions in neurons, cardiomyocytes, and other metabolically stressed cell types. Humanin exerts its cytoprotective effects through multiple mechanisms: extracellularly, it binds insulin-like growth factor-binding protein 3 (IGFBP-3) to regulate IGFBP-3's interaction with nuclear import machinery and modulate its proapoptotic signaling; intracellularly, it inhibits c-Jun NH2-terminal kinase (JNK) activation through SH3-binding protein 5 to suppress stress-induced apoptotic cascades. PNAS research established that humanin interacts with IGFBP-3 to regulate cell survival and apoptosis, characterizing a molecular basis for its anti-apoptotic activity, and subsequent work identified JNK inhibition as an additional neuroprotective mechanism in humanin-treated neuronal preparations. Humanin is a research compound with no regulatory approval in any jurisdiction; published evidence is predominantly from in vitro and preclinical models, and no human clinical trials have been completed to establish pharmacokinetic, safety, or efficacy parameters for exogenous humanin administration.